Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole switch study with slow versus rapid taper of prior atypical antipsychotic
ACTRN12605000516684Phase 4Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aripiprazole in schizophrenia and schizoaffective disorder (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Benefits of rapid versus slow tapering while taking aripiprazole and Risks of rapid versus slow tapering while taking aripiprazole. Started Apr 2006; status: recruiting.
02
Drugs
aripiprazole
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on ACTRN12605000516684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000516684.